The firm considers the deal value balanced, especially when accounting for cash and prior milestone commitments Eli Lilly had already made. Want deeper insights? InvestingPro offers exclusive access to 13 additional ProTips and comprehensive financial analysis for Eli Lilly, helping investors make informed decisions. The acquisition further deepens Eli Lilly's presence in the cardiometabolic field and expands its range of severity options, building upon the company's current leadership positions in obesity and diabetes treatments. With analyst targets ranging from $650 to $1,190 and a strong dividend history spanning 55 consecutive years, Eli Lilly continues to demonstrate its commitment to both growth and shareholder returns. In other recent news, Eli Lilly has announced an acquisition agreement with Verve Therapeutics valued at up to $1.3 billion, including an upfront payment of approximately $1.0 billion.